Last Updated On 8/6/2025 2:30:26 AM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.
Employment |
No Relationships to Disclose |
|
|
Leadership |
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests |
No Relationships to Disclose |
|
|
Honoraria |
No Relationships to Disclose |
|
|
Consulting or Advisory Role |
Company: Merck |
Recipient: You |
Company: Bristol-Myers Squibb |
Recipient: You |
Company: AstraZeneca |
Recipient: You |
Company: EMD Serono |
Recipient: You |
Company: Pfizer |
Recipient: You |
Company: Janssen |
Recipient: You |
Company: Roche |
Recipient: You |
Company: Astellas Pharma |
Recipient: You |
Company: Gilead Sciences |
Recipient: You |
Company: Strata Oncology |
Recipient: You |
Company: Abbvie |
Recipient: You |
Company: Bicycle Therapeutics |
Recipient: You |
Company: Replimune |
Recipient: You |
Company: Daiichi Sankyo |
Recipient: You |
Company: Foundation Medicine |
Recipient: You |
Company: Eli Lilly |
Recipient: You |
Company: Urogen pharma |
Recipient: You |
Company: Tyra Biosciences |
Recipient: You |
|
Speakers' Bureau |
No Relationships to Disclose |
|
|
Research Funding |
Company: Bristol-Myers Squibb |
Recipient: Your Institution |
Company: Merck |
Recipient: Your Institution |
Company: EMD Serono |
Recipient: Your Institution |
Company: Gilead Sciences |
Recipient: Your Institution |
Company: Acrivon Therapeutics |
Recipient: Your Institution |
Company: ALX Oncology |
Recipient: Your Institution |
Company: Genentech |
Recipient: Your Institution |
|
Patents, Royalties, Other Intellectual Property |
No Relationships to Disclose |
|
|
Expert Testimony |
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses |
Company: Gilead Sciences |
Recipient: You |
|
Other Relationship |
No Relationships to Disclose |
|
|
(OPTIONAL) Uncompensated Relationships |
not answered |
|
|
(OPTIONAL) Open Payments Link |
not answered |
|
|